Upregulation of the gene encoding a cytoplasmic dynein intermediate chain in senescent human cells
✍ Scribed by Izumi Horikawa; Elaine S. Parker; Gregory G. Solomon; J. Carl Barrett
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 154 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0730-2312
- DOI
- 10.1002/jcb.1169
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Normal human somatic cells, unlike cancer cells, stop dividing after a limited number of cell divisions through the process termed cellular senescence or replicative senescence, which functions as a tumor‐suppressive mechanism and may be related to organismal aging. By means of the cDNA subtractive hybridization, we identified eight genes upregulated during normal chromosome 3‐induced cellular senescence in a human renal cell carcinoma cell line. Among them is the DNCI1 gene encoding an intermediate chain 1 of the cytoplasmic dynein, a microtubule motor that plays a role in chromosome movement and organelle transport. The DNCI1 mRNA was also upregulated during in vitro aging of primary human fibroblasts. In contrast, other components of cytoplasmic dynein showed no significant change in mRNA expression during cellular aging. Cell growth arrest by serum starvation, contact inhibition, or γ‐irradiation did not induce the DNCI1 mRNA, suggesting its specific role in cellular senescence. The DNCI1 gene is on the long arm of chromosome 7 where tumor suppressor genes and a senescence‐inducing gene for a group of immortal cell lines (complementation group D) are mapped. This is the first report that links a component of molecular motor complex to cellular senescence, providing a new insight into molecular mechanisms of cellular senescence. J. Cell. Biochem. 82:415–421, 2001. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
We used an anchor polymerase chain reaction method to compare the repertoires of transcribed T-cell receptor p chain variable region Cvp) genes in cord blood T cells from neonates of hepatitis B surface antigen (HBsAg) positive (n = 40) and HBsAg negative (n = 40) women. Fifteen of the HBsAg positi